PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19073273-4	2009	In the present study, we have evaluated the effects of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, in LPS-induced pulmonary dysfunction, inflammatory changes and oxidative stress in guinea pigs.	Pioglitazone	55-67	peroxisome proliferator-activated receptor gamma	Cavia porcellus	71-119	
19073273-4	2009	In the present study, we have evaluated the effects of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, in LPS-induced pulmonary dysfunction, inflammatory changes and oxidative stress in guinea pigs.	Pioglitazone	55-67	peroxisome proliferator-activated receptor gamma	Cavia porcellus	121-131	
15692987-0	2005	Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs.	Pioglitazone	0-12	peroxisome proliferator-activated receptor gamma	Cavia porcellus	16-64	
15692987-1	2005	OBJECTIVE: To evaluate the in vivo therapeutic effect of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on the development of lesions in a guinea pig model of osteoarthritis (OA), and to determine the influence of pioglitazone on the synthesis of matrix metalloproteinase 13 (MMP-13) and interleukin-1beta (IL-1beta) in articular cartilage.	Pioglitazone	57-69	peroxisome proliferator-activated receptor gamma	Cavia porcellus	73-121	
15692987-1	2005	OBJECTIVE: To evaluate the in vivo therapeutic effect of pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist, on the development of lesions in a guinea pig model of osteoarthritis (OA), and to determine the influence of pioglitazone on the synthesis of matrix metalloproteinase 13 (MMP-13) and interleukin-1beta (IL-1beta) in articular cartilage.	Pioglitazone	57-69	peroxisome proliferator-activated receptor gamma	Cavia porcellus	123-132	
15692987-11	2005	CONCLUSION: This is the first in vivo study demonstrating that a PPARgamma agonist, pioglitazone, could reduce the severity of experimental OA.	Pioglitazone	84-96	peroxisome proliferator-activated receptor gamma	Cavia porcellus	65-74